methoxy-morpholinyl-doxorubicin has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; Lu, L; Xu, C; Yang, W; Yuan, S; Zhang, X | 1 |
| Clausen, OP; De Angelis, P; Lehne, G; Rugstad, HE | 1 |
2 other study(ies) available for methoxy-morpholinyl-doxorubicin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Toxicity Tests, Acute; Xenograft Model Antitumor Assays | 2004 |
Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells.
Topics: Aclarubicin; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Liver Neoplasms; Tumor Cells, Cultured | 1998 |